• Figure 1.

    Hemoglobin trends among dialysis patients in the United States from 2010 to 2017, New York

  • Figure 2.

    Timeline of drug development of erythropoietin (EPO) analogues

  • 1.

    Unger EF, et al. Erythropoiesis-stimulating agents: Time for a reevaluation. N Engl J Med 2010; 362:189192.

  • 2.

    Lin FK, et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 1985; 82:75807584.

  • 3.

    Szczech LA, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 2008; 74:791798.

  • 4.

    Haase VH. Therapeutic targeting of the HIF oxygen-sensing pathway: Lessons learned from clinical studies. Exp Cell Res 2017; 356:160165.

  • 5.

    Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 1995; 26:4146.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Macdougall IC, et al. Intravenous iron in patients undergoing maintenance hemodialysis. N Engl J Med 2019; 380:447458.

  • 7.

    Anker SD, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361:24362448.

Anemia and Chronic Kidney Disease: WHERE WE’VE BEEN, WHERE WE’RE GOING

Steven Fishbane Steven Fishbane, MD, is professor of medicine, division of nephrology, department of medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York.

Search for other papers by Steven Fishbane in
Current site
Google Scholar
Restricted access